research use only

Flurbiprofen Immunology & Inflammation related chemical

Name: Flurbiprofen
Brand: Selleck Chemicals
SKU: S1679
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S1679

Flurbiprofen (a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs)) is a member of the phenylalkanoic acid derivative family of non-steroidal anti-inflammatory drugs (NSAIDs).

Chemical Structure

Molecular Weight: 244.26

Jump to

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other Immunology & Inflammation related Inhibitors	Cl-amidine Bestatin (Ubenimex) Tempol Tranilast Sinomenine Geniposidic acid GI254023X (GI4023) CORM-3 Acacetin Germacrone

Solubility

In vitro
Batch:

DMSO : 48 mg/mL (196.51 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 48 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	244.26	Formula	C₁₅H₁₃FO₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	5104-49-4	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O

Mechanism of Action

In vitro	Flurbiprofen effectively inhibits the growth of various tumor cells in a dose-dependent manner and causes a noticeable change in the progression of cells through cell cycle stages in tumor cell lines derived from medulloblastoma and glioblastoma multiforme. This compound reduces the number of cells in G1 and G2, and significantly increases their numbers in S phase, suggesting that it accelerates G1/S entry, and/or delays cell exit from S to G2/M stages. It causes a minor change in the RNA level of different cyclins, there is a significant decrease in the level of cyclin B protein upon flurbiprofen treatment.
In vivo	Flurbiprofen affords significant neuroprotection from ischemic injury as evidenced by reduction in cerebral infarct volume and neurobehavioral deficit. This compound significantly reduces an early calcium dependent rise in levels of nitrite and MDA in ischemic brain regions of rats. It also reduces the proteolytic products (SBDPs) caused by ischemic activation of calcium dependent protease calpain. This chemical (5 mg/kg and 10mg/kg) significantly attenuates brain ischemia/reperfusion injury in rats, as shown by a reduction in the infarct volume, neurological deficit scores and cell apoptosis. It not only inhibits the expression of Bax protein and p-GSK-3β, but also increases the expression of Bcl-2 protein, the ratio of Bcl-2/Bax as well as the P-Akt level in rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/11687965/ [2] https://pubmed.ncbi.nlm.nih.gov/20813117/ [3] https://pubmed.ncbi.nlm.nih.gov/21624354/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05901389	Not yet recruiting	Lidocaine\|Analgesia\|Pain Postoperative\|Thoracic Surgery	Qilu Hospital of Shandong University	June 2023	Not Applicable
NCT05622656	Recruiting	Pain Postoperative	First People''s Hospital of Chenzhou	December 1 2022	Phase 4
NCT05368831	Completed	Healthy Volunteers	NorthSea Therapeutics B.V.	July 19 2022	Phase 1
NCT04805775	Completed	Desflurane\|Propofol\|Postoperative Sleep\|PSQI\|Breast Tumor	Zhongnan Hospital	October 21 2021	Not Applicable

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):